Meralgia Paresthetica: Evidence-Based Diagnosis & Treatment

Meralgia paresthetica is a burning, tingling or numb patch over the outer thigh, caused by irritation or compression of a small sensory nerve, the lateral femoral cutaneous nerve (LFCN), near the front of the hip. It can be very uncomfortable and occasionally disrupts walking, exercise or sleep, but many cases settle with the right conservative approach. Two things make the biggest difference: getting the diagnosis right, confirming the symptoms genuinely come from this nerve and not the lower back or hip, and, when treatment is needed, delivering it accurately around the nerve under ultrasound. That combination, a careful clinical examination and real-time ultrasound, is exactly what this condition needs.

What is meralgia paresthetica?

Meralgia paresthetica is a sensory nerve entrapment affecting the lateral femoral cutaneous nerve (LFCN), most often where it passes close to the anterior superior iliac spine (the bony prominence at the front of the pelvis) and under or through the inguinal ligament. Typical symptoms include:

• burning or tingling over the outer thigh;
• numbness;
• altered skin sensitivity;
• hypersensitivity to light touch;
• occasionally sharp or electric-like pain.

Because the LFCN is a purely sensory nerve, meralgia paresthetica should not normally cause muscle weakness or loss of reflexes. If there is weakness, the problem is usually coming from somewhere else, which is one reason a proper examination matters. The condition is often benign and can improve with conservative treatment, but persistent symptoms can be genuinely limiting.

Why does it happen?

The LFCN comes from the L2 and L3 nerve roots and travels through the pelvis before passing close to the front of the hip. Its most vulnerable point is usually around the inguinal ligament near the anterior superior iliac spine (ASIS). Irritation or compression there can be linked to:

• weight gain or obesity;
• pregnancy;
• tight belts or restrictive clothing;
• prolonged hip extension or standing;
• repetitive activity;
• direct trauma;
• previous pelvic, hip or abdominal surgery, or surgical positioning;
• natural variation in the course of the nerve.

A 2023 review estimated around 32 new cases per 100,000 people each year, with obesity and diabetes among the recognised associations, and a BMI over 30 roughly doubling the risk (Scholz et al., 2023). Interestingly, substantial weight loss can occasionally contribute too, possibly by reducing the protective soft tissue around the nerve.

Getting the diagnosis right: it isn't always simply "a trapped nerve"

Meralgia paresthetica is mainly a clinical diagnosis, and the history is often characteristic: sensory symptoms over the outer front of the thigh, no true muscle weakness, aggravation with standing, walking or hip extension, and sometimes relief with sitting or hip flexion. The catch is that several other conditions can mimic it, including:

• lumbar radiculopathy, particularly at L2-L3;
• femoral neuropathy;
• hip pathology;
• pelvic pathology;
• myofascial pain;
• occasionally other peripheral nerve entrapments.

This is exactly why a careful clinical examination matters, rather than simply injecting the area where it hurts. A 2024 narrative review stressed that diagnosis should bring together clinical examination, imaging and, where appropriate, nerve conduction studies, because no single test is reliable on its own.

What ultrasound adds

Ultrasound has become very useful for both diagnosing and treating meralgia paresthetica. The LFCN is a small nerve, but modern high-frequency probes can usually show it near the ASIS and inguinal ligament. On ultrasound we can look for:

• focal enlargement of the nerve;
• a darker (hypoechoic) appearance;
• an abrupt change in calibre;
• loss of the normal internal fascicular pattern;
• increased blood flow within the nerve;
• anatomical variants, and the nerve's relationship to the inguinal ligament.

A prospective study of 86 patients with suspected meralgia paresthetica found sonographic abnormalities in 95% of clinically suspected cases, commonly an abrupt calibre change, an abnormal nerve outline and increased blood flow within the nerve (Shi et al., 2021). Another study found the symptomatic nerve was significantly larger than normal, and ultrasound picked up nerve enlargement more often than MRI. A 2025 systematic review and meta-analysis confirmed that affected nerves have a significantly greater cross-sectional area than unaffected ones, and that certain more superficial or lateral anatomical variants may be more prone to compression (Powell et al., 2025).

Why does this matter so much for injections? The LFCN does not run in exactly the same place in everyone. A 2021 surgical study comparing pre-operative ultrasound with what was actually found at operation showed 100% agreement in identifying anatomical variants. A landmark-only technique assumes the nerve sits in a predictable spot relative to the ASIS; ultrasound instead lets us find the actual nerve, recognise variants, watch the needle in real time, place treatment right around the nerve, and avoid injecting the surrounding tissues by mistake.

Evidence: good, ultrasound reliably identifies the nerve and its variants

First-line treatment: reduce the source of compression

Most people should start with conservative treatment, which means finding and reducing anything that is compressing or irritating the nerve. That might involve:

• avoiding tight belts or clothing;
• adjusting work equipment or posture;
• reducing prolonged standing or hip extension;
• weight management where relevant;
• addressing biomechanical or activity-related factors.

Simple pain relief or neuropathic pain medication can occasionally help when symptoms persist. The direct evidence for any specific conservative treatment isn't strong, but spontaneous improvement is common enough that starting conservatively is sensible. A 2023 review concluded that most patients can begin with lifestyle changes, pain relief and, where needed, injection therapy before surgery is considered.

Evidence: modest, but a reasonable first step, as many settle on their own

Ultrasound-guided injection

When symptoms persist, an ultrasound-guided LFCN injection has two possible roles.

Diagnostic: temporary relief after a local anaesthetic block supports the idea that this nerve really is responsible, which is helpful when the diagnosis is uncertain.
Therapeutic: the injection can reduce pain and nerve irritability, and buy a window during which the aggravating factors can be addressed.

The injection is usually local anaesthetic alone, or local anaesthetic combined with a corticosteroid.

How effective are injections?

The evidence is mixed but generally supportive in well-selected patients. A 2020 randomised trial comparing ultrasound-guided injection, TENS and conservative care found significant pain improvement in the injection group, and concluded it was a safe option, particularly where neuropathic pain was prominent (Kilic et al., 2020). A 2021 meta-analysis of 10 studies (149 patients) reported successful outcomes in about 85% of patients after ultrasound-guided injection, compared with about 80% after surgery, though only 57 injection patients were included and there were no head-to-head randomised comparisons, so those figures need caution (Tagliafico et al., 2021).

Does corticosteroid add anything?

This is an interesting recent question. A 2023 double-blind randomised trial compared ultrasound-guided local anaesthetic plus corticosteroid against local anaesthetic alone. Both groups improved substantially, and at four weeks average pain scores were about 2.5 with steroid and 3.1 without, a difference that was not statistically significant (Palamar et al., 2023). In other words, an accurately placed injection around the nerve may itself be doing much of the work, and steroid may not be essential for everyone. The study was small (32 patients). A separate 2020 placebo-controlled study found no significant benefit of steroid over saline at 12 weeks, but importantly it did not use ultrasound, and the authors themselves suggested future placebo-controlled work should use ultrasound guidance, precisely because the nerve is so variable.

Evidence: moderate, ultrasound-guided injection helps; local anaesthetic alone may be enough

Dextrose (D5W) hydrodissection

A newer option is ultrasound-guided hydrodissection with 5% dextrose (D5W). Hydrodissection means placing fluid around the nerve to gently separate it from the surrounding fascia, aiming to reduce friction or tethering. A recent prospective, randomised, double-blind trial of 56 patients compared a single dextrose hydrodissection with a corticosteroid-based one, following both for six months. This kind of study is valuable because it tests whether a non-steroid injectate can give durable improvement, and whether the mechanical separation itself matters.

Does hydrodissection actually "free" the nerve? It's biologically plausible but not fully proven. Under ultrasound you can see the nerve separate from the adjacent fascia as fluid is injected, which may reduce mechanical tethering, improve nerve gliding and calm local irritation. But improvement afterwards doesn't prove the compression was permanently corrected, some of the benefit may come from the fluid itself and from changes in pain signalling. So it's more accurate to describe hydrodissection as a perineural treatment that reduces local nerve irritation and mechanical restriction, rather than a permanent release. I'd currently call D5W hydrodissection a promising option rather than an established first-line treatment, and it's particularly attractive when repeated steroid exposure is best avoided.

Evidence: emerging and promising, avoids repeated steroid

What about radiofrequency?

Pulsed radiofrequency of the LFCN, which modulates the nerve's signalling without deliberately destroying it, has been described for stubborn cases. Small case series report improvement in selected patients who responded temporarily to a diagnostic block but then relapsed, but the evidence is much weaker than for injection or surgery. It's best thought of as an option for persistent cases rather than routine treatment.

Evidence: limited, for selected refractory cases

When is surgery considered?

Surgery is generally reserved for persistent, disabling symptoms with a convincing diagnosis, when appropriate conservative treatment and injections have not given enough lasting relief. There are two main approaches:

• Neurolysis (decompression): the nerve is released but kept intact, so sensation is preserved.
• Neurectomy: the nerve is divided, which removes the painful signal but leaves permanent numbness over part of the outer thigh.

How effective is surgery?

A 2021 systematic review of 670 patients compared injection, neurolysis and neurectomy, reporting complete pain relief in roughly:

Revision procedures were more common after injection than surgery (Lu et al., 2021). At first glance that seems to favour surgery strongly, but it needs care: the studies were mostly observational, treatment wasn't randomised, definitions of success varied, and patients chosen for surgery often differed from those having injections. A different meta-analysis focused specifically on ultrasound-guided injection versus surgery found 85% success with injection and 80% with surgery, with no significant difference (Tagliafico et al., 2021). The wide gap between these estimates shows how limited the current evidence really is. The fair conclusion is that both injection and surgery can work, but we lack high-quality head-to-head trials, which is why starting with the least invasive effective option makes sense.

Evidence: effective for carefully selected refractory cases

What about physiotherapy?

Physiotherapy is often suggested, but there's surprisingly little good evidence that specific exercises directly decompress the LFCN, so treatment should be individualised. It can genuinely help when there are related issues such as reduced hip mobility, mechanical aggravating factors, an altered walking pattern, deconditioning or difficulty getting back to exercise. What it shouldn't be is automatically blamed on a "tight hip flexor" and treated with generic stretching, in fact, in some people pushing the hip into extension makes symptoms worse, because it increases tension across the inguinal region. As an MSK physiotherapist, my job is to work out which of these factors actually apply to you, rather than apply a one-size-fits-all programme.

Our approach to meralgia paresthetica

The most important step is to establish that the symptoms really come from the lateral femoral cutaneous nerve, because outer-thigh pain can also come from the lumbar spine, the hip or other nerves. A thorough assessment therefore looks at the distribution of symptoms, the sensory changes, a neurological examination, the lumbar spine and hip, possible compression factors, and the ultrasound appearance of the nerve itself.

If the picture is typical and mild, treatment usually starts with reducing external compression, modifying aggravating activity and monitoring symptoms. If symptoms persist, ultrasound lets us identify the nerve and its individual course, and an ultrasound-guided diagnostic and therapeutic injection can be considered, local anaesthetic helps confirm the nerve is genuinely responsible, and corticosteroid can be added when persistent irritation is suspected, though recent randomised evidence suggests local anaesthetic alone can also produce substantial improvement. If symptoms recur, options include repeat perineural treatment, ultrasound-guided D5W hydrodissection, or specialist peripheral-nerve or surgical assessment. Surgery is generally kept for cases that haven't responded adequately to less invasive treatment.

Key message

Frequently asked questions

References